Squeezing fresh lemon juice on dark background, hand squeezing fresh lemon juice close up

(Getty Images)

Is a Hims & Hers short squeeze brewing?

The company has high short interest and the stock has risen significantly in the past week. Its earnings report could be make or break for short sellers.

J. Edward Moreno

5/5/25 1:36PM

Once it was clear that Hims & Hers’ ability to sell exact copies of Ozempic and Wegovy was coming to an end, the short sellers came running. While that may have been a fruitful trade in the beginning, recent events may have created the environment for a short squeeze.

Hims has exceptionally high short interest and shares are up 48% over the past month after a partnership with Novo Nordisk was announced. The company reports earnings after the bell on Monday, which could trigger a surge in share price — or, as the hedge funds short on Hims are probably hoping — a plunge that puts it back to where it was a couple weeks ago.

Hims has roughly 33% short interest as a percentage of float, which means about a third of the available shares have been sold short but are not yet covered. When someone shorts a stock, they borrow shares and sell them with the intention of buying it back later at a lower price. Ideally for them, the price falls, and they pocket the difference (less the cost of borrowing the stock).

Short interest in the company rose in October, after the Food and Drug Administration declared that the shortage of tirzepatide, the active ingredient in Eli Lilly’s GLP-1 drugs, was over. Hims never sold compounded tirzepatide, but that announcement fueled expectations that the shortage of semaglutide — the active ingredient in Ozempic and Wegovy, which Hims does sell — would end soon after.

That did in fact happen in February, limiting Hims’ ability to continue selling copycat versions of the drug. The stock tanked by about 50% in a month, which was good news for the large chunk of traders short on the stock.

But, as the path forward for its weight-loss biz starts to take shape, the company’s stock has risen. Its announcement last week that it would partner with Novo led the stock to rise by more than 40%, and it has kept those gains.

Investors will be closely watching the company’s earnings report for more clues on where its weight-loss business is going. Short sellers will be hoping for an earnings miss or other news that tanks the stock price.

If it rises or even just keeps its gains, that means short sellers have to buy back their borrowed shares at a higher price than they sold them. For example, if a short seller sold Hims stock on April 22 at $25, today they could buy it back at $41 — a $16 loss per share. They might wait for after earnings to see if the results push the price down and help them cut their losses, but if the report causes the price to spike even more, they’ll likely run to buy back so they can limit their losses.

That frenzy could create demand, pushing the price even higher and putting other short sellers in an even more dire situation. That’s what’s known as a short squeeze.

Tasha Matsumoto, Matt Phillips

The S&P 500, Nasdaq 100, and Russell 2000 close at record highs again as Strait of Hormuz is declared open

Stocks reached new record highs as risk-on sentiment flooded back into the markets, while oil tumbled.

Chicago Bulls players Dennis Rodman (L), Scottie Pippen (C) and Michael Jordan (R) hold three of the team's four recent Larry O'Brien trophies 18 June at a rally for the team in Grant Park in Chicago.

Matt Phillips13h

With their recent surge, Intel shares just hit their highest level since the dot-com era

Intel’s surge of nearly 60% this month has the iconic American chipmaker’s stock price approaching levels last seen during the dot-com era. Bloomberg noted that shares just touched their highest intraday level since the turn of the century:

“The stock rose as much as 1.5% to $69.55, topping a peak it hit on Jan. 24, 2020. The shares are up 90% this year, after soaring 84% in 2025. Intel is now roughly 8% from its all-time closing high of $74.88, established on Aug. 31, 2000.”

That’s just the most recent late-’90s-era throwback we’ve been seeing in tech shares lately. Oracle is currently pacing for its best week since late 1999.

What’s even more remarkable, however, is that Intel’s forward price-to-earnings ratio today dwarfs the premiums the market was putting on the stock during the nuttiness of the dot-com mania.

That reflects the fact that the recent run-up in Intel shares is, essentially, giving the chip giant credit for a massive turnaround that hasn’t actually happened yet.

One also might wonder if the fact that Intel is partially owned by the US government means it’s more attractive — and therefore worth a higher premium — than other chipmakers without the state imprimatur.

Still, kind of startling.

Jake Paul v Anthony Joshua - Fighter Showcase & Open Workout

Netflix sinks following disappointing outlook as investors wait for more ad growth

Netflix shares are down more than 10% on Friday morning.

Max Knoblauch14h

J. Edward Moreno14h

Eli Lilly’s GLP-1 pill hit nearly 1,400 prescriptions in first week

Eli Lilly rose after preliminary numbers cited by Wall Street analysts showed strong uptake of its new weight-loss pill.

The FDA approved Foundayo on April 1 and shipments began on April 9. In its first week, roughly 1,400 US prescriptions were written for the drug, according to IQVIA data cited by Deustche Bank analysts in a Friday note.

Novo Nordisk, Lilly’s rival in the GLP-1 market, released its GLP-1 pill earlier this year, and early signs show that it’s expanding the market, inviting patients who were turned off by weekly injections. Novo’s pill had a stronger first week than Lilly’s, with its Wegovy pill hitting 3,071 US prescriptions in the first four days after its launch on January 5.

Lilly’s pill has an advantage over Novo’s, which is that it can be taken at any time of day, with or without food. Lilly disclosed in a February regulatory filing that it had $1.5 billion worth of prelaunch inventory ready ahead of the FDA approval — which is about as much as analysts polled by FactSet expect it to sell this year.

Eli Lilly makes the world’s bestselling drug. Can it keep the party going?

Claire Yubin Oh15h

Critical Metals jumps after Greenland’s government approves CRML to take majority control of the Tanbreez mining project

Critical Metals is up more than 25% in premarket trading on Friday after the critical mining company announced that it now owns 92.5% of the Tanbreez rare earth deposit following an approval from the government of Greenland.

With that latest government support, Critical Minerals added an additional 50.5% stake to its ownership, reportedly acquired from Rimbal Pty Ltd, per Bloomberg News. With access to eight heavy rare earth elements often used in consumer electronics and defense, the site is one of the world’s largest undeveloped rare earth deposits and a key source of rare earth supply outside of China, according to the company.

In Critical Metals’ press release, Chairman Tony Sage commented that the approval “removes the most significant structural overhang on the project and provides the clarity to advance Tanbreez to production with confidence,” especially as Tanbreez’s location offers a significant logistical advantage through its year-round direct shipping access, compared to rival projects.

With 92.5% of the project now vested in Critical Metals Corp., and the remainder owned by European Lithium Ltd., CRML now has full control of the project and is seeking to accelerate development there, with plans for a new international airport and a “150-tonne bulk sample program,” which is slated for June 2026.